Literature DB >> 12034150

Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study.

P Jourdain1, M Bellorini, F Funck, Y Fulla, N Guillard, J Loiret, B Thebault, N Sadeg, M Desnos.   

Abstract

It is well known that atrial fibrillation can lead to heart failure, and is attributed to rapid ventricular rate (tachycardia-induced cardiomyopathy). Some recent studies suggest the possible existence of an intrinsic left-ventricular factor related to atrial fibrillation, irrespective of other elements. In order to demonstrate the implication of this factor, we measured B-type Natriuretic Peptide, known as a functional marker of left-ventricular dysfunction, in 40 consecutive patients with chronic non-valvular atrial fibrillation, with low ventricular rate and absence of clinical heart failure or echocardiographic left-ventricular dysfunction. In all patients, Brain Natriuretic Peptide (BNP) plasma level was high and dramatically decreased 24 h after external electrical cardioversion (61.4 pg/ml before cardioversion, 23.5 pg/ml 1 day after cardioversion, P<0.002). Our study demonstrates that atrial fibrillation, in absence of high ventricular rate, induces an asymptomatic cardiac alteration that is not detectable by echocardiography.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034150     DOI: 10.1016/s1388-9842(02)00004-1

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  9 in total

1.  Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure.

Authors:  Borut Jug; Miran Sebestjen; Miso Sabovic; Maja Pohar; Irena Keber
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

2.  Steady-state B-type natriuretic peptide levels in patients with atrial fibrillation of various clinical backgrounds.

Authors:  Tsuneaki Sadanaga; Hideo Mitamura; Shun Kohsaka; Satoshi Ogawa
Journal:  Heart Vessels       Date:  2011-05-17       Impact factor: 2.037

3.  B-type natriuretic peptide levels in patients with paroxysmal lone atrial fibrillation.

Authors:  Jingtian Li; Lexin Wang
Journal:  Heart Vessels       Date:  2006-05       Impact factor: 2.037

4.  Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation.

Authors:  T Date; T Yamane; K Inada; S Matsuo; S Miyanaga; K Sugimoto; K Shibayama; I Taniguchi; S Mochizuki
Journal:  Heart       Date:  2006-06-01       Impact factor: 5.994

5.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

Review 6.  Prediction of atrial fibrillation development and progression: Current perspectives.

Authors:  Konstantinos Vlachos; Konstantinos P Letsas; Panagiotis Korantzopoulos; Tong Liu; Stamatis Georgopoulos; Athanasios Bakalakos; Nikolaos Karamichalakis; Sotirios Xydonas; Michael Efremidis; Antonios Sideris
Journal:  World J Cardiol       Date:  2016-03-26

7.  Natriuretic Peptides as Predictors of Atrial Fibrillation Recurrences Following Electrical Cardioversion.

Authors:  Theodoros A Zografos; Demosthenes G Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-11-29

Review 8.  Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation.

Authors:  Masako Baba; Kentaro Yoshida; Masaki Ieda
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

9.  Impact of Left Atrial Appendage Closure Combined with Catheter Ablation on Endocrine and Mechanical Cardiac Function in Patients with Atrial Fibrillation.

Authors:  Jing Yang; Ling You; Mingqing Liu; Guangming Zhang; Liang Feng; Yue Liu; Xue Geng; Jinglan Wu; Ruiqin Xie
Journal:  J Interv Cardiol       Date:  2022-03-19       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.